TLN-499 / Treeline Biosci - LARVOL DELTA

TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Treeline Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Endocrine Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Sarcoma • Small Cell Lung Cancer • Solid Tumor • Synovial Sarcoma

Treeline opens Phase I trial of TLN-499 plus venetoclax in BCL-2-dependent solid tumors (AllSci Corp) - "Massachusetts-based biotech Treeline Biosciences, Inc. has registered a first-in-human Phase I clinical trial of TLN-499, an oral BCL-XL protein degrader, in combination with AbbVie's venetoclax (Venclexta) for patients with relapsed or refractory solid tumors, including small cell lung cancer (SCLC), neuroendocrine cancer, malignant pleural mesothelioma, and synovial sarcoma. The study (NCT07713732) is scheduled to begin enrolling in Q3 2026 across three Australian sites....The open-label, multicenter, single-arm trial is structured in two parts: a dose-escalation phase followed by a dose-expansion phase, enrolling up to 120 adults with histologically confirmed relapsed or refractory disease and ECOG performance status of 0–1."

New P1 trial • Malignant Pleural Mesothelioma • Neuroendocrine Carcinoma • Small Cell Lung Cancer • Solid Tumor • Synovial Sarcoma